The polymerase chain reaction (PCR) was used to detect residual malignant disease before and after ex vivo purging with monoclonal antibodies and complement or immunomagnetic treatment of BM samples contaminated with known numbers of t(l4;18)-carrying tumor cells. Sensitivity of the PCR was demonstrated by detecting a specific t(14;18) amplification product in DNA extracted from a preparation consisting of one tumor cell among lo5 normal cells. When BM contaminated with 1% to 5% t(l4;18)-carrying cells from the B-cell lymphoma line SU-DHL-4 was subjected to two rounds of anti-B-cell pool of antibodies and complement (Ab-C) treatment a 3-to 4-log reduction of the pretreatment PCR signal was observed. A similar log-cell kill was detected ELAPSE REMAINS a major problem after autolo-R gous bone marrow transplantation (BMT) for leukemias and lymphomas. This problem may be due to inadequate antitumor therapy or contamination of the marrow graft with occult tumor cells. In an effort to remove residual tumor cells, attempts have been made to purge the marrow graft with various modalities such as chemotherapeutic agents or antibodies and complement (Ab-C).'" A significant problem in the evaluation of these methods has been that assays sensitive enough to detect minimal residual disease have been lacking. The most sensitive approach using clonogenic assays is useful for detecting 4 to 5 logs of tumor cell kiL4 However, this assay can rarely be directly applied to patient material because of the variable and poor cloning efficiency of fresh tumor isolates.
using an independent clonogenic assay confirming the utility of the PCR approach. BM contaminated with a second B-cell lymphoma cell line, OCI-Ly8, was more resistant because a third cycle of Ab-C treatment was required to obtain a similar reduction in the PCR signal. A similar 4 logs of tumor cell removal was obtained using anti-B-cell antibodies conjugated to magnetic beads. These studies demonstrate that the t(14;18) PCR can be used to detect levels of tumor cells as low as 0.001%. This approach can be used to determine the effectiveness of BM purging in patients undergoing autologous BM transplantation as well as to assess the biologic role of minimal marrow disease.
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leukemia (CML), that harbor certain chromosomal
In non-Hodgkin's lymphomas the most prevalent cytogenetic abnormality is the t( 14;18) chromosomal translocation reportedly present in up to 85% of patients with follicular lymphomas and 30% of patients with diffuse large cell This translocation involves the transfer of the bcl-2 proto-oncogene at chromosome band 18q21 to the heavy chain region of the Ig locus on chromosome 14.'4-'7 t( 14;18) translocations typically occur as errors during the process of Ig heavy chain gene rearrangement and breakpoints have been shown to cluster adjacent to J , segments on chromosome 14 and at defined sites within or flanking the bcl-2 gene on chromosome 18.'4-'6,18 The molecular clustering oft( 14;18) breakpoints on both chromosomes 14 and 18 make this translocation particularly amenable to detection by PCR.
In this study we demonstrate the utility of the PCR technique for detecting low numbers of t( 14;18)-carrying cells in experimentally contaminated BM and peripheral blood stem cell preparations before and after purging with monoclonal antibodies (MoAbs) and complement.
MATERIALS AND METHODS
Mononuclear cells were obtained from BM and peripheral blood by Ficoll-hypaque (Lymphoprep; Nycomed, Oslo, Norway) centrifugation.
Two B-cell lymphoma cell lines, SU-DHL-4 and OCI-Ly8, were provided by Dr R. Levy (Stanford University, Stanford, CA). Both cell lines are known to carry the t(14;18) chromosomal t r a n s l o~a t i o n . '~~~ Cells were maintained in RPMI 1640 (Applied Scientific, San Francisco, CA) supplemented with 10% fetal calf serum (FCS; HyClone, Logan, UT), 100 UImL penicillin, 100 kg/mL streptomycin, 50 pmol/L 2-mercaptoethanol, and 2 mmol/L L-glutamine at 37°C in 5% CO,.
The following antibodies were used in this study. B-cell antibody IF5 (CD20) was provided by J. Ledbetter (Oncogen Inc, Seattle, WA). J9 (CD9), 5149 (CDlO), and 54-35 (CD19) were provided by J. Pesando (Biomembrane Research Institute, Seattle, WA). T-cell antibodies 35.1 (CD2), 38.1 (CD3), 64.1 (CD3), 66.2 (CD4), 10.2 (CD5), 12.1 (CD6), 51.1 (CD8), and 9.3 (CD28) were provided by P. Martin (University of Washington, Seattle). Rabbit complement was purchased from Pel-Freez (Brown Deer, WI).
Tumor cells from cell lines SU-DHL-4 or OCILy8 were added to BM or peripheral blood mononuclear cells at 1% to 5% of the total cell number. Either the B-or T-cell pool of For personal use only. on November 11, 2017. by guest www.bloodjournal.org From antibodies was added plus DNAse (Sigma, St Louis, MO) at 50 U/mL. The samples were incubated on ice for 30 minutes. Complement was then added at a final concentration of 1% and the samples were incubated for 60 minutes at 37°C. The cells were then collected by centrifugation and the process repeated for the indicated number of cycles.
Immunomagneticpwging. Antibodies coupled to magnetic beads were also used to "purge" experimentally contaminated BM. IgM antibodies (5149 and 4-35) were first absorbed to uncoated magnetic beads (Dynabeads M-450; Dynal AS., Oslo, Norway) by adding 1 mg purified IgM antibody/mL of uncoated beads in 0.05 mol/L Tris-HC1 (pH 9.5) and incubated overnight at 4°C. The unabsorbed material was removed using a magnetic separator (MPC-1, Dynal AS.) and the beads were washed four times with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA). To perform the "purging" experiments, IgG antibodies and magnetic beads coated with IgM antibodies were added to BM contaminated with 5% SU-DHL-4 cells and incubated on ice for 30 minutes. Sheep antimouse IgG conjugated magnetic beads (Dynal A.S.) were then added at 40 beads per SU-DHL-4 cell and incubated for an additional 30 minutes on ice. The magnetic beads were then removed using the magnetic separator and the cells were collected by centrifugation. The adherent cells were then removed from the magnet, resuspended in PBS, and collected by centrifugation. DNA was then extracted from both the adherent and nonadherent fractions.
Tumor cell lines were labeled with 400 pCi of 'lCr (Dupont-NEN, Boston, MA) for 1 hour at 37"C. 4 The labeled cells were washed extensively and added to the mononuclear cells at the desired concentration. After Ab-C treatment the cells were collected and an aliquot of supernatant counted. Percent specific release was defined by:
"Cr release assay.
Test Release -Spontaneous Release Maximal Release -Spontaneous Release x 100
Maximal release was obtained by treating the samples with 1% Known numbers of tumor cells were plated in 0.25 mL of Iscove's modified Dulbecco's medium (IMDM; GIBCO, Grand Island, NY) containing 20% FCS and 1.1% methylcell~lose.~ When BM was cultured for granulocyte-macrophage colony forming unit (CFU-GM) determinations 17% placental conditioned media was added. For Ab-C purging experiments mononuclear cells were first irradiated (1,000 R) before the addition of viable tumor cells. Either tumor cell or CFU-GM colonies were scored 7 to 14 days later using an inverted microscope. All determinations were performed in duplicate.
DNA was prepared by standard phenol-chloroform extraction and ethanol precipitation?' DNA, 2 to 5 kg, was used for each PCR reaction. The concensus Ig J, oligonucleotide (MC4) and the bcl-2 specific oligonucleotide (MC5) were used.M Two globin oligonucleotides termed B-globin 1 and 2 were prepared and used in some reactions.22 PCR reactions were performed using 2.5 U of ampli-TAQ (Cetus, Emelyville, CA) for 30 cycles in a Perkin-Elmer thermocycler (Cetus). Cycle conditions included a 55°C annealing (2 minutes), 72°C extension (3 minutes), and a 94°C denaturation (1 minute). Reaction products were then electrophoresed on 1.5% agarose gels and transferred to I-probe blotting membranes (Bio-Rad, Richmond, CA).23 Hybridization was performed overnight at 55°C using the kinased internal oligonucleotide MC6 (5'-GTATITAGTTATGGCCTATACACrAT"rrGT- sodium dodecyl sulfate (SDS) at 60°C for 30 to 45 minutes.
Autoradiographywas performed at -70°C with intensifying screens.
RESULTS
To determine the effectiveness of tumor cell lysis by Ab-C treatment, a chromium release assay was initially used. The results of "Cr release studies are shown in Fig 1. In these experiments tumor cells (either SU-DHL-4 or OCI-Ly8) were radiolabeled with "Cr and added to normal mononuclear BM cells at 5% of the total cell number. Either the single antibody IF5 or the pool of anti-B-cell antibodies was then added followed by complement. After a single round of treatment approximately 80% of maximal chromium release was obtained using the IF5 antibody alone, whereas over 95% chromium release was obtained using the anti-B-cell pool of antibodies. Additional rounds of Ab-C treatment resulted in slightly more chromium release. The pool of anti-T-cell Ab-C or complement treatment alone resulted in only a small amount of chromium release. This assay was relatively insensitive at levels above 90% chromium release and could not be directly correlated to log-cell kill, although it was useful for measuring the relative efficiency of lysis. Toxicity of Ab-C treatment was assessed by evaluating CFU-GM growth of Representative data from four experiments.
Abbreviations: -, complement alone; T, T-cell pool of Ab-C; 6, B-cell *Number of cells before Ab-C treatment.
pool of Ab-C.
normal BM before and after treatment. No significant suppression of CFU-GM was found after Ab-C treatment (Table 1) . To more quantitatively assess the log-cell kill resulting from Ab-C treatment a clonogenic assay was used. The cloning efficiency of the t( 14;18)-carrying cell line SU-DHL-4 was determined to be approximately 5%, whereas that for OCI-Ly8 was significantly less (data not shown). In Table 2 the relative numbers of clonogenic SU-DHL-4 cells were determined before and after treatment with Ab-C. When irradiated BM cells contaminated with SU-DHL-4 cells were either plated directly or after two rounds of anti-T-cell pool Ab-C treatment, approximately 5.5 to 8.5 colonies, respectively, were obtained for every 125 cells plated. After two rounds of treatment with the anti-B-cell pool of Ab-C samples originally containing 1.25 x lo5 SU-DHL-4 cells resulted in 7.5 colonies, indicating that there was greater than a 3-log decrease in the number of clonogenic cells. These studies established that the SU-DHL-4 cell line was susceptible to Ab-C lysis and the efficiency of lysis could be quantitatively measured by the clonogenic assay.
Conditions were then established for using the PCR to detect minimal residual tumor cells before and after Ab-C treatment. The target nucleotide sequences for specific amplification by PCR consisted of t( 14;18) breakpoint DNA. The genetic structure of the t( 14;18) chromosomal translocation in the SU-DHL-4 cell line and the experimental rationale for t(14;18) PCR are shown in Fig 2. The t(14;18) results in translocation of the bcl-2 gene on chromosome 18 to the J region of the Ig heavy chain gene on chromosome 14. This translocation appears to result from errors in D-J joining and, therefore, the breakpoint on chromosome 14 can occur within any of the six J segments." In the SU-DHL-4 cell line the breakpoint occurred adjacent to the 54 segment." Because one of the oligonucleotide primers (MC4) used for PCR was complementary to a consensus sequence within all of the J regions, three different-sized PCR products were observed when this consensus oligonucleotide was used in conjunction with a bcl-2 specific oligonucleotide on DNA from SU-DHL-4. The three products correspond to specific priming within the bcl-2 gene on chromosome 18 in conjunction with priming at the three remaining J segments (54, J5, J6) on chromosome 14.
The results of a dilution series to demonstrate the sensitivity of the t(14;18) PCR assay in our studies is shown in Fig 3. Three major amplification products were detected at approximately 1,300, 600, and 230 bp using SU-DHL-4 cell line DNA. At increasing dilutions the largest amplification product of 1,300 bp was lost first, followed by the intermediate 600-bp product, and finally the smallest 230-bp product. Under these conditions a signal could be detected to a lo5 dilution of SU-DHL-4 cells that corresponded to DNA from less than five tumor cells in the reaction. Though the PCR reaction is difficult to quantitate, a dosedependent decrease in PCR signal can be seen (Fig 3) . At very low dilutions (ie, to this dose dependency was not apparent. Because of the semiquantitative nature of PCR, low-level positive samples (ie, lo-' dilution) are necessary to control for the efficiency of the reaction.
The efficiency of purging with Ab-C using mononuclear cells contaminated with SU-DHL-4 cells as detected by PCR is shown in Fig 3. In these experiments SU-DHL-4 cells were added to normal BM or peripheral blood stem cells at 5% of the total number. Two rounds of Ab-C treatment were performed with either the anti-B-or anti-T-cell pool of Ab-C in the presence of DNAse. After treatment with the pool of anti-B-cell antibodies (lane B) there was an approximate 3-to 4-log decrease in the intensity of the 230-bp signal when compared with the dilution series (lanes lo-' to Treatment with the anti-T-cell antibody pool (lane T) resulted in no significant decrease in the PCR signal. As an internal control, oligonucleotide primers for P-globin end-labeled with 32P were also For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Fig 3. Antibody-mediated purging of SU-DHL4 cells from an excess of normal mononuclear cells. Tenfold dilutions (from lo-' to lo-') of SU-DHL4 cells were added to mononuclear cells and DNA was prepared followed by PCR. For purging experiments SU-DHL4 cellswore added to EM cells at 5% contamination. The samples were treated with either the T-cell pool (lane T), or the &cell pool (lane B) of Ab-C for two rounds. PCR was performed using 5 pg of DNA. The primers used for amplification were MC4, MC5, pglobin 1, and p-globin 2. Southern blot analyses were performed using the radiolabeled internal oligonucleotide MC6 and pglobin-2 as probes. Reaction products from 2 pg of SU-DHL4 DNA are shown in lane labeled DHL4. The band at approximately 500 bp is likely due to a hybrid molecule of the 600-bp strand hybridizing to the 270-bp strand, which is commonly observed in PCR where two or more products are amplified.
added to the reaction. In each sample the expected 150-bp globin product (lowest band in all lanes) was detected at equal intensity, indicating that the PCR was performing uniformly in all reactions.
Despite two rounds of Ab-C treatment using the anti-Bcell antibody pool, a faint 230-bp signal was still detectable in samples contaminated with SU-DHL-4 cells. Therefore, additional rounds of Ab-C were performed. In addition, a second B-lymphoma cell line OCI-Ly8, which also has a t(14;18) translocation, was studied. The results of multiple rounds of Ab-C treatment of samples initially containing 5% tumor cells are shown in Fig 4. Using the SU-DHL-4 cell line, an intense PCR signal was detected after a single round of Ab-C treatment; however, this was greatly decreased after two or more cycles of treatment. Using OCI-Ly8 cells, a significant decrease in the intensity of the PCR signal was not observed until three rounds of Ab-C treatment had been performed and the signal was decreased even further after a fourth round of treatment. In this experiment, the Southem blot was probed only with the 32P-labeled internal oligonucleotide MC6. However, the 150-bp PCR product resulting from f3-globin amplification was detected in equal intensity using ethidium bromide staining (Fig 4) . The apparent resistance of OCI-Ly8 cells to Ab-C treatment was not explained by the inability of these cells to bind all of the B-cell antibodies in the pool as determined by immunofluorescence analysis (data not shown). Although these data indicate that the OCI-Ly8 cell For personal use only. on November 11, 2017. by guest www.bloodjournal.org From line was more resistant to Ab-C lysis than the SU-DHL-4 line, additional rounds of Ab-C treatment were capable of inducing effective cellular lysis as shown by the decrease of the specific amplification product.
The use of antibodies conjugated to magnetic beads to "purge" BM contaminated with SU-DHL-4 cells was also explored using PCR to detect residual tumor cells before and after treatment. To do this, the B-cell pool or T-cell pool of antibodies was added to BM contaminated with 5% SU-DHL-4 cells. After addition of second stage sheep antimouse conjugated beads, absorbed cells were removed using a magnetic separator. DNA was prepared from both the absorbed and unabsorbed cells and PCR performed. Results are shown in Fig 5. Using the B-cell pool of antibodies, at least 4 logs of SU-DHL-4 cells were removed from the contaminated BM (signal intensity less than a lo-' dilution). When DNA was prepared from the cells absorbed to the magnetic beads, a strong PCR signal was obtained indicating that DNA from the removed cells could be recovered from the magnetic beads. The expected PCR signal was obtained when samples were treated with the T-cell pool of antibodies.
DISCUSSION
In autologous BMT for lymphomas and leukemias, occult tumor cells that contaminate the marrow autograft may contribute to the high rate of relapse after this procedure. Using standard pathologic or immunohistochemical techniques, BM containing less than 1% tumor cells may be judged to be free of neoplastic disease because this represents the lower limits of sensitivity for these wellestablished techniques. In this report, we describe studies using the PCR to detect occult tumor cells in purged BM preparations.
The PCR is theoretically capable of detecting a single tumor cell in an analyzed specimen consisting of 10s to 106 total cells, making it an ideal technique to search for residual disease in preparations that are minimally contaminated. Using a dilution series with known levels of contamination by tumor cells, a PCR signal was detected in our studies at a tumor cell dilution of l:lOs confirming the extreme sensitivity of this technique for detecting t( 14;18)-carrying cells as shown by several previous studie~.6.'.~' The major criticism of the PCR technique is the difficulty in quantitating the reaction. This lacking was especially apparent at low levels of residual tumor cells. However, semiquantitation was demonstrable when comparing samples with high levels of tumor cell contamination versus those with low levels of tumor cell contamination (ie, IO-' to IO-'v to Using BM preparations contaminated with 1% to 5% t(l4;18)-carrying lymphoma cells (SU-DHL-4), a 3 to 4 log-cell kill was obtained by two rounds of treatment with Ab-C. The specific reduction in contaminating tumor cells was measured as a semiquantitative reduction in the t(14; 18) PCR signal. The reliability of the PCR result was confirmed by using a clonogenic assay that gave equivalent results of tumor cell reduction by the Ab-C treatments. Use of an independent clonogenic assay was necessary because one possible technical problem with using the PCR in this setting could have resulted from contaminating DNA liberated by the lysed tumor cells. Amplification oft( 14;18) breakpoint sequences in the released DNA may have resulted in an underestimation of the log-cell kill. However, the inclusion of adequate amounts of DNAse appeared to effectively eliminate DNA released by the lysis procedure. This potential source of a false-positive PCR signal assumes importance when patient BMs are purged because detection of any t(l4;18)-specific signal by PCR would be an indication that further rounds of Ab-C treatment are necessary (such as that required here for the OCI-Ly8 cell line). Antibodies conjugated to magnetic beads were also used to purge BM of experimentally contaminated SU-DHL-4 cells. In these experiments, greater than 4 logs of tumor cells were removed. In addition, SU-DHL-4 DNA could be recovered from the cells absorbed to the magnetic beads, which is in contrast to Ab-C-treated samples where the DNA from lysed cells is degraded by the DNAse that is added.
False-negative results are another potential problem when using the PCR in this setting because, in practice, Ab-C treatment results in the elimination of target cells with consequent loss of a specific PCR signal. This problem could be avoided by using immunomagnetic techniques because DNA from the removed cells could be examined for specific breakpoint sequences by PCR. This may particularly be the case in clinical settings where the level of contamination of marrow grafts will likely be lower than the experimentally induced 1% to 5% used in this study. To ensure that the loss of PCR signal was not due to a technical artifact, P-globin primers were added to the reaction mix and resulted in the amplification of P-globin transcripts in all samples, indicating that the PCR was performing properly. Under these conditions, a negative PCR result does not guarantee that the graft is free of t(l4;18)-carrying cells but rather indicates that no malignant cells are present in the examined portion (lo' to lo6 cells). Although more sensitive by several orders of magnitude than other methods for detection of residual disease, the PCR is limited in part by how much DNA can be added to the reaction (1 to 10 pg total). In addition, because PCR requires cellular lysis and DNA extraction, only a portion of the purged marrow can be examined, with the possibility that unexamined portions contain low numbers of neoplastic cells (less than 1 in lo'). Prospective studies using these sensitive assays are required to determine how effective the purging process needs to be and what the minimal contaminations are that lead to eventual relapse of the patient. Our results indicate that PCR is capable of detecting low levels of minimal residual disease and showing decrease to levels below 0.001%.
Limitations of the use of PCR to monitor the extent of ex vivo purging may also result from the lack of suitable target sequences specific for an individual patient's malignancy. For this study, we chose to amplify nucleotide sequences corresponding to t(14;18) breakpoint DNA. The t(14;18) translocation is a useful tumor marker for several reasons. First, it is the most common chromosomal translocation in non-Hodgkin's lymphomas, being present in approximately 85% of follicular neoplasms and 30% of diffuse large-cell lymphomas." Second, most breakpoints for this translocation are remarkably conserved, clustering on chromosome 18 in two major areas termed the major and minor breakpoint region^.'^^'^^'^ On chromosome 14, breakpoints cluster adjacent to or within the heavy chain joining region sequences. This clustering allows for PCR amplification of genomic breakpoint DNA from tumor specimens using appropriately selected generic primers to result in DNA fragments of ideal length that can be efficiently amplified. However, a significant minority of t( 14;18) breakpoints occur sporadically outside the two chromosome 18 cluster regions at sites flanking the bcl-2 gene and, thus, cannot be amplified with the generic primers.
For other types of lymphomas, the myc gene translocations in high-grade lymphoma^^^*^' and t( 11;14) in low-grade lymphoma^^^^^' may be amenable to PCR detection, although breakpoint clustering on chromosomes 8 and 11 may not be as constrained as in the t(14;18). Because the majority of lymphomas and leukemias carry translocations,28 breakpoint DNA fragments hold promise as the best candidates for tumor-specific markers amenable to PCR detection. As molecular studies of these various cytogenetic abnormalities advance, the PCR will presumably be applicable to an increasing fraction of hematolymphoid malignancies. It is also likely that other approaches based on construction of tumor-specific oligonucleotide primers such as the CDRIII PCR will extend the applicability of PCR for detection of minimal residual disease. 29 We have demonstrated the utility of the PCR assay for detecting minimal residual disease before and after purging of BM preparations with Ab-C or antibodies conjugated to magnetic beads. In this analysis, the tumor cell targets were cultured lymphoma cells that experimentally contaminated the grafts at known numbers. This approach should be useful for determining the efficacy of various purging techniques and for the prospective analysis of patient material after transplantation to monitor for disease recurrence. This method will hopefully allow for the detection and treatment of minimal disease, and help elucidate the biologic role of minimal residual marrow disease following autologous BMT.
